Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Post-Market Study to Assess iTind Safety in Comparison to UroLift

NCT: NCT04757116 · RECRUITING

NCT IDNCT04757116
StatusRECRUITING
Start Date2022-09-26
Completion2030-05-31
SponsorOlympus Corporation of the Americas (INDUSTRY)
First posted
Last updated

Brief Summary

The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑